Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA3 | P07451 | 2/20 | 0.41 |
| ▸ | CA4 | P22748 | 2/20 | 0.41 |
| ▸ | CA6 | P23280 | 2/20 | 0.41 |
| ▸ | CA5A | P35218 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.41 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.37 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3164648 | 0.97 | DNM1 (0.47) | GSRNFKB1CA12CA1CA2 | |
| SCHEMBL10884825 | 0.97 | DNM1 (0.47) | GSRNFKB1CA12CA1CA2 | |
| SCHEMBL584899 | 0.97 | DNM1 (0.47) | GSRNFKB1CA12CA1CA2 | |
| SCHEMBL6339082 | 0.94 | DNM1 (0.44) | GSRNFKB1CA12CA1CA2 | |
| SCHEMBL3487034 | 0.94 | ENPEP (0.36) | GSRNFKB1ENPEPALDH1A1 | |
| SCHEMBL350694 | 0.94 | NFKB1 (0.50) | GSRNFKB1CA12CA1CA2 | |
| SCHEMBL351414 | 0.90 | NFKB1 (0.47) | GSRNFKB1CA12CA1CA2 | |
| SCHEMBL20597340 | 0.90 | DNM1 (0.53) | GSRNFKB1CA12CA1CA2 | |
| SCHEMBL350445 | 0.90 | DNM1 (0.53) | GSRNFKB1CA12CA1CA2 | |
| SCHEMBL163475 | 0.90 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004342-A1 | LFA-1 Inhibitors and Use Thereof | SODA KUNIYASU | 2010-01-07 | — | — | US | claimed |
| US-20060281820-A1 | Lfa-1 inhibitors and use thereof | SODA KUNIYASU | 2006-12-14 | — | — | US | claimed |
| EP-4605121-A1 | DELIVERY PARTICLES BASED ON AMINE-THIOL-ENE CONJUGATES AND DERIVATIVES | Encapsys, LLC (US) | 2025-08-27 | — | — | EP | disclosed |
| WO-2024086501-A9 | DELIVERY PARTICLES BASED ON AMINE-THIOL-ENE CONJUGATES AND DERIVATIVES | ENCAPSYS, LLC (US) | 2024-12-26 | — | — | WO | disclosed |
| WO-2024086501-A1 | DELIVERY PARTICLES BASED ON AMINE-THIOL-ENE CONJUGATES AND DERIVATIVES | ENCAPSYS, LLC (US) | 2024-04-25 | — | — | WO | disclosed |
| CN-111108235-B | Electrolytic copper plating bath | 株式会社杰希优 | 2022-05-03 | — | — | CN | disclosed |
| CN-111108235-A | Electrolytic copper plating bath | 株式会社杰希优 | 2020-05-05 | — | — | CN | disclosed |
| US-9796753-B2 | N-substituted indenoisoquinolines and syntheses thereof | PURDUE RESEARCH FOUNDATION (US) | 2017-10-24 | — | — | US | disclosed |
| EP-3112349-A2 | A PROCESS FOR PREPARING N-SUBSTITUTED INDENOISOQUINOLINES | Purdue Research Foundation (US) | 2017-01-04 | — | — | EP | disclosed |
| US-20160229888-A1 | N-SUBSTITUTED INDENOISOQUINOLINES AND SYNTHESES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-08-11 | — | — | US | disclosed |
| US-9399660-B2 | N-substituted indenoisoquinolines and syntheses thereof | PURDUE RESEARCH FOUNDATION (US) | 2016-07-26 | — | — | US | disclosed |
| WO-2009093454-A1 | FOOD COMPOSITION, FEED COMPOSITION COMPRISING THE FOOD COMPOSITION, AND METHOD FOR FEEDING ANIMAL BY USING THE FEED COMPOSITION | JICHI MEDICAL UNIVERSITY (JP) | 2009-07-30 | — | — | WO | disclosed |
| US-20090053142-A1 | CONTRAST AGENTS | WYNN DUNCAN | 2009-02-26 | — | — | US | disclosed |
| US-20080318995-A1 | N-Substituted Indenoisoquinolines and Syntheses Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-12-25 | — | — | US | disclosed |
| EP-1989179-A1 | CONTRAST AGENTS | GE Healthcare AS (NO) | 2008-11-12 | — | — | EP | disclosed |
| EP-1960366-A2 | N-SUBSTITUTED INDENOISOQUINOLINES AND SYNTHESES THEREOF | Purdue Research Foundation (US) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007094683-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2007-08-23 | — | — | WO | disclosed |
| WO-2007059008-A2 | N-SUBSTITUTED INDENOISOQUINOLINES AND SYNTHESES THEREOF | PURDUE RESEARCH FOUNDATION (US) | 2007-05-24 | — | — | WO | disclosed |
| US-20060281820-A1 | Lfa-1 inhibitors and use thereof | SODA KUNIYASU | 2006-12-14 | — | — | US | disclosed |
| US-4009208-A | N,N'-HEPTAMETHYLENEBIS(4-METHOXYBENZAMIDE) | STERLING DRUG INC. (US) | 1977-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090053142-A1 | CONTRAST AGENTS | IPO4, TPO, IPO11 | GSR 4535/4885NFKB1 1447/4885CA12 539/4885 |
| US-20080318995-A1 | N-Substituted Indenoisoquinolines and Syntheses Thereof | GNAQ, NRAS, NPM1 | GSR 2306/4885NFKB1 980/4885CA12 4854/4885 |
| US-20160229888-A1 | N-SUBSTITUTED INDENOISOQUINOLINES AND SYNTHESES THEREOF | GNAQ, NRAS, NPM1 | GSR 2306/4885NFKB1 980/4885CA12 4854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.